Site for S2212 SHORTER ANTHRACYCLINE-FREE CHEMO IMMUNOTHERAPY ADAPTED TO PATHOLOGICAL RESPONSE IN EARLY TRIPLE NEGATIVE BREAST CANCER (SCARLET) A RANDOMIZED PHASE III STUDY

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Early Triple Negative Breast Cancer
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Participants must have histologically confirmed ER-negative, PR-negative, and HER2-negative breast cancer (TNBC)
    2. Participants must have AJCC 8 anatomic tumor clinical stage
    3. Participants must not have T4/N+, any N3, or inflamm

You may not be eligible for this study if the following are true:

    1. Participants have received prior systemic therapy or radiation therapy with curative intent for the current breast cancer
    2. Participants have had previous definitive ipsilateral breast surgery for the current breast cancer
    3. Par


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.